Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

34.64
+0.41441.21%
Volume:3K
Turnover:89.34K
Market Cap:44.17M
PE:- -
High:34.64
Open:34.48
Low:34.41
Close:34.23
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.76
T/O Rate:0.20%
Dividend:0.08
Dividend Rate:0.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Moderately bullish activity in Eli Lilly with shares down 1.26%

TIPRANKS
·
Sep 01

Top Midday Stories: Stocks Fall, Oil Rises Amid Renewed Fighting in Middle East; Utility Shares Fall After California Wildfire Legislation

MT Newswires Live
·
Aug 31

H.C. Wainwright trims Ascendis target, says litigation overhang removed

TIPRANKS
·
Aug 31

Ascendis Pharma a/S : H.c. Wainwright Cuts Target Price to $344 from $345

THOMSON REUTERS
·
Aug 31

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
·
Aug 31

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
Aug 31

Eli Lilly Expands Beyond Weight-Loss Dominance With Potential $2.88B Autoimmune Deal

Stock News
·
Aug 31

Ascendis Pharma price target lowered to $330 from $333 at Jefferies

TIPRANKS
·
Aug 31

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31
More